319 Frequency and acceptance of CDSS-generated STOPP/START signals - SI Table SI1.2. Continued START criteria (n=31) All countries Belgium (BE) Switzerland (CH) Ireland (IE) The Netherlands (NL) Frequency (N) Acceptance (%) Frequency (N) Acceptance (%) Frequency (N) Acceptance (%) Frequency (N) Acceptance (%) Frequency (N) Acceptance (%) E 7. Folic acid supplement in patients taking methotrexate. 2 100% 1 100% 1 100% 0 N/A 0 N/A C 4. Topical prostaglandin, prostamide or beta-blocker for primary open-angle glaucoma. 0 N/A 0 N/A 0 N/A 0 N/A 0 N/A G 3. Topical vaginal oestrogen or vaginal oestrogen pessary for symptomatic atrophic vaginitis. 0 N/A 0 N/A 0 N/A 0 N/A 0 N/A Data was ordered from highest to lowest frequency of generated signals. STOPP criteria C7, D3, D6, D7, E5, F1, G1, H1, J2, J4 and M1 and START criteria C4 and G3 were in no case generated. STOPP A2 (“Any drug prescribed beyond the recommended duration, where treatment duration is well defined”) could not be coded and was therefore not incorporated in the CDSS. START A1 (“Vitamin K antagonists, direct thrombin inhibitors or factor Xa in the presence of chronic atrial fibrillation”) and START A2 (“Aspirin 75-160 mg once daily in the presence of chronic atrial fibrillation, where Vitamin K antagonists or direct thrombin inhibitors or factor Xa inhibitors are contraindicated”) were merged into one algorithm (START A1/2). START I1 (“Seasonal trivalent influenza vaccine annually) and I2 (“Pneumococcal vaccine at least once after age 65 according to national guidelines”) were excluded from analysis. 4
RkJQdWJsaXNoZXIy MTk4NDMw